Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Financial Performance - Eli Lilly is set to release its fourth-quarter financial results on February 6, 2025, with expected earnings of $5.08 per share, a significant increase from $2.49 per share in the same quarter last year [1] - The company projects quarterly revenue of $13.43 billion, up from $9.35 billion a year earlier [1] Revenue Growth Expectations - For the full year 2024, Eli Lilly anticipates worldwide revenue to be approximately $45.0 billion, reflecting a 32% growth compared to the previous year, slightly below the consensus estimate of $45.50 billion [2] Stock Performance and Analyst Ratings - Eli Lilly shares increased by 2% to close at $842.18 [2] - Analysts have provided various ratings and price targets for Eli Lilly, with Wells Fargo maintaining an Overweight rating and reducing the price target from $1,000 to $970 [4] - B of A Securities reinstated a Buy rating with a price target of $997, while Barclays cut its price target from $1,025 to $975, both maintaining Overweight ratings [4] - Morgan Stanley reiterated an Overweight rating with a price target of $1,106, and BMO Capital raised its price target from $1,001 to $1,101 while maintaining an Outperform rating [4]